Kernicterus Treatment Market Report 2026

The kernicterus treatment market size has grown steadily in recent years. It will grow from $3.03 billion in 2025 to $3.1 billion in 2026 at a compound annual growth rate (CAGR) of 2.1%. The growth in the historic period can be attributed to increasing number of surgical procedures and skin injuries, higher prevalence of keloid formation in specific populations, established clinical use of steroid injections, growing demand for aesthetic dermatology services, availability of multiple treatment modalities.

The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 2.2%. The growth in the forecast period can be attributed to advancements in laser and phototherapy technologies, rising awareness of scar management solutions, increasing preference for non-surgical treatments, expansion of dermatology clinics in emerging economies, growing adoption of at-home scar treatment products. Major trends in the forecast period include rising demand for minimally invasive keloid treatments, growing use of combination therapy approaches, increasing adoption of laser and phototherapy solutions, expansion of homecare and topical scar management products, focus on reducing keloid recurrence rates.

The growing prevalence of neonatal jaundice is expected to drive the expansion of the kernicterus treatment market in the coming years. Neonatal jaundice, commonly referred to as jaundice in newborns, is a widespread and usually benign condition marked by yellowing of an infant’s skin and the whites of the eyes. The incidence of neonatal jaundice is increasing due to rising rates of preterm births, as premature infants often have immature liver function, which limits their ability to process and eliminate bilirubin efficiently. Kernicterus treatment is widely used in cases of neonatal jaundice to manage symptoms and provide supportive care. This treatment involves removing blood from the infant and replacing it with blood containing lower bilirubin levels, thereby reducing bilirubin concentration and improving the affected child’s quality of life. For example, in October 2023, according to reports published by the National Library of Medicine, a US-based biomedical library, approximately 60% of term infants and 80% of preterm infants develop jaundice within their first week of life, and nearly 10% of breastfed infants remain jaundiced at one month of age. Therefore, the rising prevalence of neonatal jaundice is anticipated to propel the growth of the kernicterus treatment market.

Rising healthcare expenditure is also contributing to the growth of the kernicterus treatment market. Healthcare expenditure refers to total spending on medical services, equipment, and technologies aimed at improving health outcomes. The increase in healthcare spending is driven by the growing demand for advanced medical technologies, as hospitals and clinics invest in innovative equipment and digital solutions to enhance patient care and outcomes. Higher healthcare expenditure supports kernicterus treatment by facilitating early detection of neonatal jaundice and ensuring timely and effective medical intervention to prevent severe neurological damage. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based government agency, national health expenditures rose by 7.5% in 2023 to reach $4.9 trillion, averaging $14,570 per person and accounting for 17.6% of the Gross Domestic Product (GDP). Medicare spending increased by 8.1% to $1.02 trillion, representing 21% of total national health expenditures. Consequently, increasing healthcare expenditure is driving the growth of the kernicterus treatment market.

Major companies and organizations operating in the kernicterus treatment market are increasingly prioritizing the development of innovative solutions, such as integrated neonatal jaundice screening and advanced phototherapy systems, to support early diagnosis, ensure timely treatment, and prevent kernicterus-related neurological damage in newborns. Integrated neonatal jaundice screening and advanced phototherapy systems combine diagnostic and therapeutic technologies that accurately measure bilirubin levels and deliver effective light-based therapy. These systems enable early detection of jaundice and safe reduction of bilirubin levels, thereby preventing kernicterus and long-term brain injury in newborns. For example, in December 2024, the Wellbeing Foundation Africa (WBFA), a Nigeria-based non-governmental health organization, in partnership with Reckitt, a UK-based consumer health company, launched Project Oscar - Light For Life, a nationwide initiative focused on neonatal jaundice screening, treatment, and kernicterus prevention. The program equips healthcare facilities with modern phototherapy devices and bilirubinometers, supports healthcare worker training, and educates mothers to address harmful misconceptions. Unlike traditional fragmented care models, Project Oscar adopts a comprehensive, prevention-oriented approach that integrates technology, capacity building, and community engagement to reduce neonatal mortality and long-term disabilities associated with kernicterus.

Major companies operating in the kernicterus treatment market are GE HealthCare, Philips Healthcare, Drägerwerk AG, Natus Medical Incorporated, Atom Medical Corporation, Phoenix Medical Systems, Fanem Ltda, Medela AG, Olympic Medical, Nice Neotech Medical Systems, Baxter International Inc., Fresenius Kabi, Grifols S.A, CSL Limited, Octapharma AG, Kedrion S.p.A, Biotest AG, Terumo Corporation, Haemonetics Corporation, Macopharma.

North America was the largest region in the kernicterus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kernicterus treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kernicterus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the kernicterus treatment market by increasing the cost of imported laser systems, phototherapy equipment, and specialized dermatology consumables. Treatment segments such as laser therapy, phototherapy, and injectable medications are most affected, particularly in North America and Europe due to reliance on cross-border medical device manufacturing. Hospitals and clinics face higher procurement and maintenance expenses, which may influence overall treatment pricing. However, tariffs have also encouraged local manufacturing, strengthened regional supply chains, and supported long-term cost efficiency for keloid treatment solutions.

The kernicterus treatment market research report is one of a series of new reports that provides kernicterus treatment market statistics, including kernicterus treatment industry global market size, regional shares, competitors with a kernicterus treatment market share, detailed kernicterus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kernicterus treatment industry. This kernicterus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kernicterus treatment refers to the clinical interventions used to prevent or manage kernicterus, a serious and irreversible form of brain injury that develops in newborns as a result of extremely elevated levels of unconjugated bilirubin, known as severe neonatal hyperbilirubinemia. The main objective of treatment is to rapidly lower bilirubin concentrations and prevent bilirubin from crossing the blood-brain barrier, thereby reducing the risk of neurological damage.

The primary treatment types for kernicterus include phototherapy, exchange transfusion, pharmacological supportive therapy, and supportive neurological care. Phototherapy is a therapeutic approach that utilizes specific wavelengths of light to induce beneficial biological effects in the body. In neonatal care, phototherapy is most frequently employed to manage hyperbilirubinemia (jaundice) in newborns. Treatment is delivered through non-invasive phototherapy (light-based methods), injectable blood products, intravenous immunoglobulin (IVIG), and albumin, and is utilized by end users such as hospitals, neonatal intensive care units (NICUs), specialty neonatal centers, and academic and research institutes.

The kernicterus treatment market consists of revenues earned by entities by providing services such as diagnosis and monitoring of neonatal hyperbilirubinemia, administration of phototherapy, exchange transfusion procedures, pharmacological supportive care, and neurological follow-up and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The kernicterus treatment market also includes sales of phototherapy devices, blood and blood products for exchange transfusion, intravenous immunoglobulin (IVIG), albumin, and other supportive therapeutic products used in kernicterus management. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.